
Lab Alert: New Test NT-proBNP Replaces CHFP Assay

Beginning Tuesday, November 11, 2025, Nebraska Medicine will implement the NT-proBNP assay (PBNP) as part of our ongoing efforts to enhance cardiac biomarker testing.

As part of this change, the Chronic Heart Failure Peptide (CHFP) assay will be discontinued on Friday, November 21, 2025. To further support this transition, the PROBNP test to ARUP will remain available until December 1, 2025.

Please implement the new test as soon as your interface has been updated.

The NT-proBNP assay supports early identification of acute heart failure, which is essential for timely clinical intervention. NT-proBNP is a stable biomarker with a longer half-life than BNP, making it more suitable for laboratory-based testing and consistent clinical interpretation.

It is important to remember that our current assay, CHFP, measures BNP while our new assay measures NT-proBNP. Do not compare historical BNP results with new NT-proBNP results.

NEW TEST INFORMATION

NT-proBNP [PBNP]

- Specimen Type: Serum and lithium heparin plasma
- Unacceptable: EDTA plasma (previously accepted)
- Updated Stability:
 - 24 hours at room temperature
 - 3 days refrigerated
 - 30 days frozen
- Reference Intervals (pg/mL):

Age Group	Males	Females
<50 years	≤ 103	≤ 178
50–75 years	≤ 284	≤ 317
>75 years	≤ 434	≤ 457

TEST BUILD

Order Code	OrderName	ResultCode	ResultName	ResultUnits	RESULT LOINC	CPT
PBNP	NT-proBNP	PBNP	NT-proBNP	pg/mL	33762-6	83880

For questions, please contact:

Ria C. Fyffe-Freil, Ph.D., NRCC, Director of Clinical Chemistry
rfyffefreil@unmc.edu | Office: 402-552-7204 | Pager: 402-888-6436